FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004704773> ?p ?o ?g. }

• W2004704773 endingPage "1960" @default.
• W2004704773 startingPage "1960" @default.
• W2004704773 abstract "The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial randomly assigned 76,693 men between 55 and 74 years of age to annual PSA screening in combination with digital rectal examination or to usual care.1 After 7 years of (complete) follow-up, screening was associated with increased prostate cancer incidence (relative risk [RR] = 1.2; 95% confidence interval [CI] = 1.2 to 1.3) but had no effect on prostate cancer–specific (RR = 1.1; 95% CI = 0.75 to 1.7) or allcause (RR = 0.98; 95% CI = 0.92 to 1.0) mortality. Similar results were observed after 10 years (67% of sample; RR = 1.1; 95% CI = 0.80 to 1.5). Up to 52% of the men assigned to usual care underwent a PSA test at some point during the trial, and 44% of all trial participants had undergone PSA screening prior to entry. The European Randomized Study of Screening for Prostate Cancer (ERSPC) randomly assigned 182,000 men aged 50 to 74 years from 7 countries to PSA testing every 2 to 7 years (depending on the center and year) or to usual care.1 Data from 2 other study centers were excluded for reasons not specified in the study protocol. The levels of PSA for diagnostic evaluation ranged from 2.5 to 4.0 μg/L (1 center used 10 μg/L for several years). After a median of 9 years, the incidence of prostate cancer was higher in the screened group (net increase of 34 per 1000 men), but there was no statistically significant difference in prostate cancer–specific mortality (RR = 0.85; 95% CI = 0.73 to 1.0). A prespecified subgroup analysis of 162,243 men aged 55 to 69 years found that screening was associated with reduced prostate cancer–specific mortality (RR = 0.80; 95% CI = 0.65 to 0.98; absolute risk reduction = 0.07 percentage point), for an estimated 1410 men invited to screening and 48 treated to prevent 1 prostate cancer–specific death. After publication of the main ERSPC results, 1 participating center (Göteborg, Sweden) reported results separately. It found PSA screening (threshold of 2.5 to 3.0 μg/L) every 2 years in 20,000 men aged 50 to 64 years to be associated with increased prostate cancer incidence (hazard ratio = 1.6; 95% CI = 1.5 to 1.8) and decreased risk for prostate cancer–specific mortality (RR = 0.56; 95% CI = 0.39 to 0.82; absolute risk reduction = 0.34 percentage point) after a median of 14 years. Outcomes for 60% of participants were included in the main ERSPC report." @default.
• W2004704773 created "2016-06-24" @default.
• W2004704773 creator A5062959891 @default.
• W2004704773 date "2012-04-06" @default.
• W2004704773 modified "2023-10-17" @default.
• W2004704773 title "Two large trials show prostate screening has limited reduction in mortality" @default.
• W2004704773 cites W2068376654 @default.
• W2004704773 doi "https://doi.org/10.1002/cncr.27560" @default.
• W2004704773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22488667" @default.
• W2004704773 hasPublicationYear "2012" @default.
• W2004704773 type Work @default.
• W2004704773 sameAs 2004704773 @default.
• W2004704773 citedByCount "0" @default.
• W2004704773 crossrefType "journal-article" @default.
• W2004704773 hasAuthorship W2004704773A5062959891 @default.
• W2004704773 hasBestOaLocation W20047047731 @default.
• W2004704773 hasConcept C120665830 @default.
• W2004704773 hasConcept C121332964 @default.
• W2004704773 hasConcept C121608353 @default.
• W2004704773 hasConcept C126322002 @default.
• W2004704773 hasConcept C168563851 @default.
• W2004704773 hasConcept C2775941076 @default.
• W2004704773 hasConcept C2776235491 @default.
• W2004704773 hasConcept C2780101318 @default.
• W2004704773 hasConcept C2780192828 @default.
• W2004704773 hasConcept C2781406297 @default.
• W2004704773 hasConcept C29456083 @default.
• W2004704773 hasConcept C44249647 @default.
• W2004704773 hasConcept C61511704 @default.
• W2004704773 hasConcept C71924100 @default.
• W2004704773 hasConcept C82789193 @default.
• W2004704773 hasConceptScore W2004704773C120665830 @default.
• W2004704773 hasConceptScore W2004704773C121332964 @default.
• W2004704773 hasConceptScore W2004704773C121608353 @default.
• W2004704773 hasConceptScore W2004704773C126322002 @default.
• W2004704773 hasConceptScore W2004704773C168563851 @default.
• W2004704773 hasConceptScore W2004704773C2775941076 @default.
• W2004704773 hasConceptScore W2004704773C2776235491 @default.
• W2004704773 hasConceptScore W2004704773C2780101318 @default.
• W2004704773 hasConceptScore W2004704773C2780192828 @default.
• W2004704773 hasConceptScore W2004704773C2781406297 @default.
• W2004704773 hasConceptScore W2004704773C29456083 @default.
• W2004704773 hasConceptScore W2004704773C44249647 @default.
• W2004704773 hasConceptScore W2004704773C61511704 @default.
• W2004704773 hasConceptScore W2004704773C71924100 @default.
• W2004704773 hasConceptScore W2004704773C82789193 @default.
• W2004704773 hasIssue "8" @default.
• W2004704773 hasLocation W20047047731 @default.
• W2004704773 hasLocation W20047047732 @default.
• W2004704773 hasOpenAccess W2004704773 @default.
• W2004704773 hasPrimaryLocation W20047047731 @default.
• W2004704773 hasRelatedWork W1540855474 @default.
• W2004704773 hasRelatedWork W1966688579 @default.
• W2004704773 hasRelatedWork W1992694633 @default.
• W2004704773 hasRelatedWork W1997912154 @default.
• W2004704773 hasRelatedWork W2055063381 @default.
• W2004704773 hasRelatedWork W2065473534 @default.
• W2004704773 hasRelatedWork W2118723455 @default.
• W2004704773 hasRelatedWork W4256273657 @default.
• W2004704773 hasRelatedWork W99274037 @default.
• W2004704773 hasRelatedWork W2787309891 @default.
• W2004704773 hasVolume "118" @default.
• W2004704773 isParatext "false" @default.
• W2004704773 isRetracted "false" @default.
• W2004704773 magId "2004704773" @default.
• W2004704773 workType "article" @default.